Skip to main content

Advertisement

Table 4 Patient Characteristics in the Two Subjects With Tardive Dyskinesia Reported as an Adverse Event

From: Evaluating movement disorders in pediatric patients receiving risperidone: a comparison of spontaneous reports and research criteria for TD

  Case 1 Case 2
Gender Female Male
Age 9 y 7 y
Diagnosis Attention-deficit/hyperactivity disorder – oppositional defiant disorder Disruptive behavior disorder
Intelligence quotient (IQ) 40 52
NCBRF total score     
   Baseline 47 42
   Endpoint 11 31
Timepoint Risperidone dose (mg/day) Dyskinesia score Risperidone dose (mg/day) Dyskinesia score
   Baseline 0.300 0 0.300 0
   Week 1 0.667 0 0.778 0
   Week 2 0.914 0 1.000 0
   Week 3 1.114 0 1.000 1
   Week 4 1.200 0 1.000 0
   Week 8 1.090 0 1.540 0
   Week 12 1.000 0 1.600 0
   Week 16 1.000 3 1.580 0
   Week 20 1.000 2 0.300 0
   Week 24 0.813 1   
   Week 36 0.800 1   
   Week 48 0.783 9   
  1. NCBRF indicates Nisonger Child Behavior Rating Form.